NCK Pharma » Recent updates

Insight on USFDA approval of pralsetinib to treat non-small lung cancer

Posted on15 Sep 2020

TagsBlueprint Medicines Corporation, pralsetinib

Comments0

Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™...

What is hybrid clinical trial?

Posted on15 Sep 2020

Comments0

A hybrid trial is a type of clinical trial which includes both traditional and pragmatic clinical trial elements. Randomized controlled trials are generally consider as the standard for evaluating efficacy and...

Strides Pharma to acquire 54% stake in SteriScience

Posted on15 Sep 2020

Tagsacquisition in pharma, Strides Arcolab, strides aspen, Strides Shasun

Comments0

Strides Pharma Science will invest Rs 135 crore over the next 24 months to acquire around 54 percent stake in SteriScience Pharma Pvt Ltd. This will make SteriScience the company’s...

Aurobindo Pharma partners with BIRAC to develop Covid-19 vaccine

Posted on15 Sep 2020

TagsAurobindo, covi9 19 vaccine, COVID-19

Comments0

Aurobindo Pharma is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines. The vaccine candidate is based on a proprietary vaccine delivery platform. BIRAC has facilitated the...

Insight on First approved COVID-19 vaccine Sputnik V

Posted on11 Aug 2020

TagsCOVID-19, Gamaleya National Research Centre, nCoV-19 vaccine, Sputnik V

Comments0

Russia has announced the launch of first approved covid-19 vaccine. The Covid-19 vaccine brand name is Sputnik V. Sputnik V is developed by Gamaleya Research Institute in collaboration with the...

Lupin gets exclusive rights to market and distribute 2 complex injectable assets from ForDoz Pharma

Posted on07 Aug 2020

TagsForDoz Pharma, inlicensing in pharma, Lupin

Comments0

Pharma major Lupin Limited announced that its US based wholly-owned subsidiary Lupin Pharmaceuticals Inc., has entered into an agreement with ForDoz Pharma Corp (ForDoz) for granting Lupin the exclusive rights...

Cofsils brand expansion with face masks launch

Posted on07 Aug 2020

TagsCofsils

Comments0

Cofsils, a leading brand under Cipla Health Ltd., which offers a complete solution for sore throat and cough related issues, has launched the Cofsils Face Mask that provides three levels...

Zydus Cadila’s ZyCoV-D in Phase II clinical trials for COVID-19

Posted on07 Aug 2020

TagsCOVID-19, nCoV-19 vaccine, ZyCoV-D

Comments0

Zydus Cadila’s ZyCoV-D is the plasmid DNA vaccine to prevent COVID-19. ZyCoV-D was found to be safe and well tolerated in the phase I clinical trial. The company will commence...

Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA

Posted on28 Jul 2020

Tagsdrug licensing, licensing deal in pharma

Comments0

Lynk Pharmaceuticals (Hangzhou, China) is pleased to announce exclusive licensing agreements with Kobe University (Kobe, Japan) and with RIKEN Research Institute (Saitama, Japan) to develop RAS inhibitors with a novel...

Novavax, FDB agreement for large scale manufacturing of COVID-19 vaccine candidate

Posted on28 Jul 2020

TagsFUJIFILM Diosynth Biotechnologies, influenza vaccine, nCoV-19 vaccine, Novavax

Comments0

NovavaxInc, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and FUJIFILM Diosynth Biotechnologies (FDB), a world leading CDMO for biologics, viral vaccines and gene therapies, announced an...

Pfizer-BioNTech agreement with U.S. Gov for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2

Posted on28 Jul 2020

TagsBioNTech, COVID-19, pfizer

Comments0

Pfizer Inc. and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s...

Insight on Novartis’s first-of-its-kind not-for-profit medicine portfolio for symptomatic treatment of COVID-19

Posted on28 Jul 2020

TagsCOVID-19, nCoV-19 vaccine, novartis, sandoz

Comments0

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in...

Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based SARS-CoV-2 vaccine

Posted on21 Jul 2020

TagsBioNTech, COVID-19, nCoV-19 vaccine, pfizer

Comments0

Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2. BNT162 mRNA-based vaccine is currently in development,...

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial published in The Lancet Journal

Posted on21 Jul 2020

Tagscovi9 19 vaccine, COVID-19, nCoV-19 vaccine

Comments0

ChAdOx1 Covid-19 vaccine in clinical study The Oxford shot is one of the front runners in the vaccine race and is already undergoing a combined clinical Phase II/III trials in...

DCGI approved Itolizumab to treat COVID-19 patients with moderate to severe acute respiratory distress

Posted on11 Jul 2020

TagsBiocon, Itolizumab

Comments0

India’s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for “restricted emergency use” to treat COVID-19 patients with moderate to severe acute respiratory distress. Considering...

Aurobindo Pharma hives off its biosimilars business to subsidiary CuraTeQ Biologics

Posted on05 Jun 2020

TagsAurobindo, Biosimilar, CuraTeQ Biologics

Comments0

Aurobindo Pharma hives off its biosimilars business to wholy-owned subsidiary ‘CuraTeQ Biologics Private Limited’ for a cash consideration of ₹361.46 crore. The Hyderabad-based drugmaker will transfer its biosimilars business, including...

AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer

Posted on05 Jun 2020

TagsAccent Therapeutics, AstraZeneca, codevelopment deal in pharma

Comments0

Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. Lexington, Mass.-based...

Roche’s Elecsys IL-6 test received USFDA EUA

Posted on05 Jun 2020

TagsCOVID-19, Roche, USFDA emergency use authorization

Comments0

Roche announced that the US Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys IL-6 test. This test measures levels of the biomarker interleukin...

Market Exclusivity Case Study: XIFAXAN (rifaximin)

Posted on07 May 2020

Tags505(j) ANDA, ANDA, Bausch, MARKET EXCLUSIVITY, Patent infringement case, sandoz

Comments0

Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, which is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment...

Aleor Dermaceuticals receives EIR from US FDA for Karakhadi formulation facility

Posted on07 May 2020

Tags483, 483 observations, Alembic, Aleor Dermaceuticals, EIR

Comments0

Aleor Dermaceuticals Ltd. (Aleor), a 60:40 joint venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has received Establishment Inspection Report (EIR) from the United States...

Recent updates

Insight on USFDA approval of pralsetinib to treat non-small lung cancer

What is hybrid clinical trial?

Strides Pharma to acquire 54% stake in SteriScience

Aurobindo Pharma partners with BIRAC to develop Covid-19 vaccine

Insight on First approved COVID-19 vaccine Sputnik V

Lupin gets exclusive rights to market and distribute 2 complex injectable assets from ForDoz Pharma

Cofsils brand expansion with face masks launch

Zydus Cadila’s ZyCoV-D in Phase II clinical trials for COVID-19

Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA

Novavax, FDB agreement for large scale manufacturing of COVID-19 vaccine candidate

Pfizer-BioNTech agreement with U.S. Gov for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2

Insight on Novartis’s first-of-its-kind not-for-profit medicine portfolio for symptomatic treatment of COVID-19

Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based SARS-CoV-2 vaccine

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial published in The Lancet Journal

DCGI approved Itolizumab to treat COVID-19 patients with moderate to severe acute respiratory distress

Aurobindo Pharma hives off its biosimilars business to subsidiary CuraTeQ Biologics

AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer

Roche’s Elecsys IL-6 test received USFDA EUA

Market Exclusivity Case Study: XIFAXAN (rifaximin)

Aleor Dermaceuticals receives EIR from US FDA for Karakhadi formulation facility

Executive Program in Biopharma Business Development and Strategic Management

KPE-C-062 KPE’s Certificate Course in Selling Skills for Medical Representatives

KPE-C-080 Certificate Course in Pharma Business Development & Licensing

KPE-C-079 KPE’s 1 Week Fundamental Training on Drug Discovery to Commercialization Pathway

KPE-C-077 – Fundamental Training on Data Integrity in pharmaceutical and biopharmaceutical industry

KPE-C-064N KPE’s 1 Month Certificate Course in Pharma Sales Management

KPE-C-103 Executive Program in Global Drug Regulatory Affairs [EPGDRA]

KPE-C-075 Fundamental Training on Pharma Marketing Plan Development

KPE-C-074 Fundamental Training on Monoclonal Antibody

KPE-C-073 Fundamental Training on Regulatory Affairs Advance Strategic Planning

KPE-C-072 Fundamental Training on 505B(2) Application Submission

KPE-C-071 Advance Diploma in Drug and Medical Device Regulatory Affairs (DRA + MDRA Dual Specialization)

Certification Courses

Corporate Training

Your form has been submitted

Server Side Error

Error

Recent updates

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Please sign in first

Not a member?

Certification Courses

Corporate Training